Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

HOUSTON, Dec. 29, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas.

The release as fetched from its publisher. moleculin.com ↗